Here you will find the last news about TAVR

1) New Study Confirms TAVR Durability at 5 Years

The ADVANCE study was designed to evaluate the safety and effectiveness of transcatheter aortic valve replacement (TAVR) with self-expanding prosthesis CoreValve in “real world” patients with symptomatic, severe aortic stenosis at high surgical risk.

Read the conclusions of this study

 

2) An Important Study Shows That Renal Function Must Be Cared for in TAVR

Renal impairment affects 25% of all patients who undergo TAVR. In this sense, evidence on the relation between TAVR and this condition is still limited, particularly as regards patients who require dialysis.

Read more on this study

 

3) End of Discussion on the Impact of Pacemaker After TAVR?

Pacemaker implantation after TAVR is quite common. However, its short- and long-term clinical impact is still controversial. This study is the largest meta-analysis so far on the relation between TAVR and pacemaker implantation, and it offers interesting conclusions regarding both short- and long-term outcomes.

Read the full abstract 

 

4) It Is a Fact: Cerebral Protection in TAVR Has Proved to Reduce Stroke and Death

This work upholds the idea that cerebral protection devices in patients who have undergone TAVR through a transfemoral access reduce significantly the risk for stroke and death.

Read the full abstract 

 

5) Conscious Sedation in TAVR: Is It Advisable?

Conscious sedation during TAVR offers the advantage of reducing the time spent in the cath lab and in the critical care unit, the global duration of hospital stay, and, obviously, costs. However, there still are questions on the safety of this strategy compared to general anesthesia.

This study sheds light on these issues. Read it 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...